Epilepsy Treatment via Thalamus Bistable Opsin Gene Therapy
Summary
USPTO published patent application US20260091135A1 for Modulight Bio Ltd. covering methods of treating epilepsy using thalamus-administered bistable type II opsin gene therapy with light activation. The application (No. 19403102) was filed November 27, 2025, and published April 2, 2026. The invention targets drug-resistant epilepsy via optogenetic modulation of thalamic neural circuits.
What changed
USPTO published patent application US20260091135A1 for Modulight Bio Ltd. covering methods of treating epilepsy via thalamus-targeted optogenetic therapy. The method involves administering a polynucleotide encoding a bistable type II opsin with ER export/trafficking signals into a thalamus nucleus, enabling trafficking to axonal presynaptic terminals, followed by light activation at a specific wavelength. CPC classifications include A61K 48/005 (gene therapy), A61N 5/06 (laser therapy), and C12N 15/86 (viral vectors).\n\nPharmaceutical and biotech companies developing neurological gene therapies should review this patent for freedom-to-operate implications. Healthcare providers and research institutions conducting epilepsy research may need to consider licensing requirements if commercializing similar optogenetic treatments. No compliance deadlines or penalties are associated with this patent publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF EPILEPSY
Application US20260091135A1 Kind: A1 Apr 02, 2026
Assignee
Modulight Bio Ltd.
Inventors
Yotam ELDAR, Yoav KFIR
Abstract
Methods of treating epilepsy are provided. Accordingly, there is provided a method of treating epilepsy in a subject in need thereof, the method comprising: (a) administering into a thalamus nucleus of the subject a therapeutically effective amount of a polynucleotide encoding a bistable type II opsin attached to a heterologous ER export signal and/or membrane trafficking signal which enables trafficking of said bistable type II opsin to axonal presynaptic terminals; and (b) exposing a neural region of said subject to light in a wavelength that activates said bistable type II opsin, wherein said neural region comprises a cell body and/or an axon of said thalamus nucleus.
CPC Classifications
A61K 48/005 A61K 9/0085 A61K 48/0075 A61N 5/06 A61P 25/08 C07K 14/723 C12N 15/86 A61K 38/00 A61N 2005/0635 C07K 2319/01 C12N 2750/14143
Filing Date
2025-11-27
Application No.
19403102
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.